Inhibikase Therapeutics regains Nasdaq compliance

Inhibikase Therapeutics announced that it received written notice on July 17, 2023 from the Listing Qualifications Staff of The Nasdaq Stock Market indicating that Inhibikase Therapeutics has regained full compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2), and that Inhibikase is in compliance with all applicable listing standards.